JOURNAL OF INFECTIOUS DISEASES

metrics 2024

Transforming Research into Real-World Solutions

Introduction

The JOURNAL OF INFECTIOUS DISEASES, published by OXFORD UNIV PRESS INC, is a leading peer-reviewed journal dedicated to advancing the understanding of infectious diseases through high-quality research. With an impressive impact factor reflecting its prominence in the field—ranking in the Q1 category for both Immunology and Allergy and Infectious Diseases—this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike. Its extensive history, spanning over a century since its inception in 1904, highlights its established authority and commitment to the field. Based in the United Kingdom, the journal covers essential topics from clinical management to epidemiological trends, providing vital insights that inform practice and policy. Although the journal is not open access, it remains accessible to a wide audience, ensuring that critical research continues to drive innovation and best practices in infectious disease management.

Metrics 2024

SCIMAGO Journal Rank2.39
Journal Impact Factor5.00
Journal Impact Factor (5 years)4.70
H-Index276
Journal IF Without Self5.00
Eigen Factor0.05
Normal Eigen Factor9.86
Influence1.88
Immediacy Index0.80
Cited Half Life9.90
Citing Half Life5.60
JCI1.39
Total Documents15796
WOS Total Citations43095
SCIMAGO Total Citations250931
SCIMAGO SELF Citations11255
Scopus Journal Rank2.39
Cites / Document (2 Years)4.55
Cites / Document (3 Years)4.46
Cites / Document (4 Years)4.24

Metrics History

Rank 2024

Scopus

Infectious Diseases in Medicine
Rank #30/344
Percentile 91.28
Quartile Q1
Immunology and Allergy in Medicine
Rank #26/233
Percentile 88.84
Quartile Q1

IF (Web Of Science)

IMMUNOLOGY
Rank 47/181
Percentile 74.30
Quartile Q2
INFECTIOUS DISEASES
Rank 15/132
Percentile 89.00
Quartile Q1
MICROBIOLOGY
Rank 29/161
Percentile 82.30
Quartile Q1

JCI (Web Of Science)

IMMUNOLOGY
Rank 24/181
Percentile 86.74
Quartile Q1
INFECTIOUS DISEASES
Rank 16/132
Percentile 87.88
Quartile Q1
MICROBIOLOGY
Rank 20/161
Percentile 87.58
Quartile Q1

Quartile History

Similar Journals

CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Advancing the Frontiers of Immunological Research
Publisher: OXFORD UNIV PRESSISSN: 0009-9104Frequency: 12 issues/year

Clinical and Experimental Immunology, published by Oxford University Press, is a premier journal that has been a cornerstone in the field of immunology since its inception in 1966. With an ISSN of 0009-9104 and an E-ISSN of 1365-2249, this journal holds a significant position in academic research, currently ranking in the Q2 category for both Immunology and Allergy (2023). Its impactful contributions are reflected in its Scopus rankings, where it stands at Rank #63 out of 233 in Immunology and Allergy, placing it in the 73rd percentile, and Rank #73 out of 236 in Immunology and Microbiology. Researchers, healthcare professionals, and students will find this journal an invaluable resource for cutting-edge studies, reviews, and clinical advancements in the ever-evolving domain of immunology. While the publication does not offer open-access options, it remains a pivotal platform for disseminating knowledge that impacts both clinical practice and experimental research.

VIRAL IMMUNOLOGY

Connecting cutting-edge research with clinical practices in viral immunology.
Publisher: MARY ANN LIEBERT, INCISSN: 0882-8245Frequency: 10 issues/year

Viral Immunology, published by Mary Ann Liebert, Inc, stands as a prominent journal dedicated to advancing the understanding of the interplay between viral infections and host immune responses. With a strong focus on immunology, molecular medicine, and virology, the journal provides a platform for the dissemination of high-quality research findings and innovative methodologies that could shape the future of these critical fields. Although it currently holds a Q3 rating across its relevant categories and a respectable ranking within the Scopus database, Viral Immunology continues to strive for excellence with a commitment to publishing influential research that informs both academic and clinical practices. The journal accepts submissions in various formats—original research, reviews, and commentaries—catering to a diverse readership that includes researchers, professionals, and students engaged in the biological and medical sciences. Readers can anticipate insightful articles that address urgent challenges in immunological responses to viral infections, paving the way for new therapeutic strategies and public health initiatives.

JOURNAL OF MEDICAL VIROLOGY

Advancing Virology: Pioneering Research for a Healthier Tomorrow.
Publisher: WILEYISSN: 0146-6615Frequency: 12 issues/year

JOURNAL OF MEDICAL VIROLOGY is a prestigious academic publication dedicated to advancing the field of virology and infectious diseases. Published by WILEY, this journal has established itself as a cornerstone within the scientific community since its inception in 1977, and it will continue to provide cutting-edge research until 2024. With an impressive impact factor that places it in the Q1 quartile for both Infectious Diseases and Virology, the journal ranks 14 out of 344 in Medicine - Infectious Diseases and 6 out of 80 in Immunology and Microbiology - Virology according to Scopus metrics. Its focus encompasses a broad spectrum of topics, including viral pathogenesis, diagnostics, treatment strategies, and epidemiology, making it an essential resource for researchers, clinicians, and students alike. Although not an open-access journal, it provides valuable insights and accessible content for subscribers and libraries. The ongoing commitment to high-quality peer-reviewed articles makes JOURNAL OF MEDICAL VIROLOGY a vital platform for disseminating knowledge and fostering innovation in virology and related fields.

AIMS Allergy and Immunology

Advancing the Frontiers of Allergy and Immunology
Publisher: AMER INST MATHEMATICAL SCIENCES-AIMSISSN: 2575-615XFrequency: 4 issues/year

AIMS Allergy and Immunology is a prestigious open access journal dedicated to advancing knowledge in the fields of allergy and immunology. Published by the American Institute of Mathematical Sciences (AIMS), this journal provides a vibrant platform for researchers, practitioners, and scholars to share groundbreaking findings and insights. Recognized for its commitment to disseminating high-quality research since its inception in 2017, AIMS Allergy and Immunology contributes significantly to the understanding of complex immunological mechanisms and allergic responses, thus playing a pivotal role in enhancing clinical practices and therapeutic strategies. With its ISSN 2575-615X, the journal aims to facilitate a robust exchange of ideas and promote collaboration within the scientific community. Researchers and practitioners are encouraged to access the latest studies and reviews, which are all freely available online, ensuring that vital information reaches a global audience without barriers. Together, we can tackle the challenges posed by allergies and immune disorders through rigorous scientific inquiry and innovation.

EUROPEAN JOURNAL OF IMMUNOLOGY

Illuminating the Path to Immunological Advances
Publisher: WILEYISSN: 0014-2980Frequency: 12 issues/year

Welcome to the European Journal of Immunology, a premier peer-reviewed journal dedicated to advancing the field of immunology and allergy research. Established in 1971 and published by Wiley, this esteemed journal has been consistently ranked in the top quartile (Q1) across its categories, highlighting its significant impact within the scientific community. With an impressive Scopus ranking, the journal occupies the 64th position in Immunology and Allergy and the 74th in the broader sector of Immunology and Microbiology, demonstrating its vital role in driving innovation and knowledge in immunological studies. The European Journal of Immunology publishes high-quality original research, comprehensive reviews, and insightful commentary, making it an indispensable resource for researchers, healthcare professionals, and students dedicated to understanding the complexities of the immune system. Although not an open-access journal, it offers various subscription options to ensure that institutions and individuals can access pivotal research that shapes the future of immunology.

Emerging Microbes & Infections

Pioneering discoveries in microbial health.
Publisher: TAYLOR & FRANCIS LTDISSN: Frequency: 1 issue/year

Emerging Microbes & Infections is a premier open access journal, published by Taylor & Francis Ltd since 2012, dedicated to advancing the understanding of microbial infections and their implications in human health. With an impressive Q1 ranking across multiple categories—including Drug Discovery, Epidemiology, Immunology, and Infectious Diseases—this journal is at the forefront of research in the microbiological sciences. Covering a diverse range of topics, it serves as a vital resource for researchers, healthcare professionals, and students alike. The journal's commitment to open access ensures worldwide dissemination of cutting-edge findings, fostering collaboration and innovation in tackling challenges posed by emerging infections. As part of the thriving academic community in the United Kingdom, Emerging Microbes & Infections plays a crucial role in shaping the future of infectious disease research and public health.

Infectious Diseases

Advancing the Frontiers of Infectious Disease Research
Publisher: TAYLOR & FRANCIS LTDISSN: 2374-4235Frequency: 12 issues/year

Infectious Diseases, published by TAYLOR & FRANCIS LTD, is a leading academic journal dedicated to advancing research in the field of infectious diseases and microbiology. With an impressive impact factor and categorized in Q1 in multiple areas including Immunology and Microbiology, this journal serves as a critical platform for researchers, practitioners, and students to disseminate their findings and stay abreast of current advancements. The journal is recognized for its rigorous peer-review process and aims to foster innovation and collaboration across disciplines from 2015 to 2024. It boasts a robust Scopus ranking, positioning it favorably among the top-tier of journals in the relevant fields, making it an essential resource for anyone involved in infectious disease research. Access options are available, ensuring that the latest research is accessible to a global audience, thus emphasizing the journal's commitment to promoting knowledge and understanding in the ever-evolving landscape of infectious diseases.

Immuno

Advancing Immunology Through Open Access Innovation
Publisher: MDPIISSN: Frequency: 4 issues/year

Welcome to Immuno, a pioneering open-access journal published by MDPI that serves as a key platform for the dissemination of innovative research in the fields of immunology, biochemistry, and genetics. Established in 2021, this journal has rapidly established itself within the academic community, currently ranking in the 53rd percentile in Medicine (miscellaneous) and 50th percentile in Biochemistry, Genetics, and Molecular Biology according to Scopus metrics. With a commitment to advancing our understanding of immune mechanisms and their applications in health and disease, Immuno is dedicated to publishing high-quality peer-reviewed articles that contribute valuable insights to both researchers and practitioners. Positioned in the heart of Switzerland, its global accessibility and diverse editorial board are a testament to its aim to promote knowledge exchange among scientists, practitioners, and students alike. Explore the latest discoveries and advancements in immunological research through Immuno, where your contributions help shape the future of this critical area of study.

GERMS

Championing research that transforms health outcomes worldwide.
Publisher: EUROPEAN ACAD HIV-AIDS & INFECTIOUS DISEASESISSN: 2248-2997Frequency: 4 issues/year

GERMS is a multidisciplinary journal published by the EUROPEAN ACAD HIV-AIDS & INFECTIOUS DISEASES, dedicated to advancing knowledge in the fields of epidemiology, immunology, infectious diseases, and microbiology. Since its inception in 2011, the journal has provided a crucial platform for researchers and practitioners to share innovative studies, clinical findings, and public health insights, with an eye on improving health outcomes globally. With an ISSN of 2248-2997 and a consistent publication trajectory leading up to 2024, GERMS is recognized in the third quartile across several categories, reflecting its growing impact and relevance in the scientific community. Authors and readers benefit from a range of access options, fostering the dissemination of vital research findings. As a journal situated in Romania, it also addresses regional health challenges while contributing to the broader discourse on infectious diseases and public health. GERMS is not just a repository of knowledge, but a vital resource for those engaged in combating infectious diseases and promoting health equity.

ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA

Shaping the future of microbiological inquiry.
Publisher: AKADEMIAI KIADO ZRTISSN: 1217-8950Frequency: 4 issues/year

ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA is a distinguished academic journal published by AKADEMIAI KIADO ZRT, focusing on significant advancements in the fields of microbiology, immunology, and infectious diseases. Established in 1994, this journal serves as a vital platform for researchers, professionals, and students keen on exploring the complexities of microbial interactions and immune responses. With a current Impact Factor reflecting its rank within the Q3 categories for Immunology, Microbiology, and Infectious Diseases, it retains a critical position in disseminating innovative research. Although not open access, the journal provides extensive insights disseminated through various academic databases, ensuring a broad reach within the scholarly community. Its convergence over three decades indicates a robust commitment to excellence in scientific inquiry and knowledge sharing. As it moves towards the future, ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA continues to uphold its legacy of fostering collaborative research initiatives that contribute to the understanding and treatment of microbial diseases globally.